![]() |
Disease Ontologies and Information Workshop19th – 20th June 2008 Disease ontologies and information: its linkage to genes, gene ontologies and phenotypic information. Workshop Dates: 19th – 20th June 2008 Motivation Health research generally as well as target driven drug discovery requires researchers in industry1 to identify those genes which are not only amenable to intervention but also to be disease relevant. Hence, disease information linked to genetic information is of high importance. While gene information is now in good shape and structured, disease information is widespread and diffuse and difficult to access from a bioinformatics point of view. Some databases exist on the web with different scope and content. Links between genes and diseases are of major interest in industry target identification and also links between compounds and diseases. The workshop will help to shed more light on the disease – gene links. Scope The workshop shall focus on the question: where we can find good information about diseases, especially diseases with known or suspected linkage to genes, and integrate this with information available in biomedical informatics data resources. Furthermore, how can we best link this information to disease models in animal and in particular mouse phenotypes, where such models are used as a proxy for disease information in humans. Finally, the outcome from the workshop will be communicated into the ELIXIR WP7 roadmap which is focussed on biomedical standards and ontologies (www.elixir-europe.org). 1 By Industry we mean researchers in the pharmaceutical, consumer goods, nutrigenomics, cosmaceutical and agriculture industries which all have an interest in health, disease and phenotypes. Discussion topics and areas are:
Organisers and contacts: The Coordinator of the EBI Industry Programme is Dr. Dominic Clark (EMBL-EBI). The Scientific Coordinator for this workshop is Prof. Michael Ashburner (University of Cambridge and former joint head of EMBL-EBI). The programme advisors are Dr. Ian Harrow (Pfizer), Ms. Wendy Filsell (Unilever), Dr. Matt Hall (GSK) and Dr. Bertram Weiss (Bayer Schering Pharma). Please send any questions regarding the strategic intent and programme to Dominic Clark. Accommodation will be in the new accommodation blocks at Homerton College in Cambridge (http://www.homerton.cam.ac.uk/). Please send any questions regarding logistics to Liz Ford (ford@ebi.ac.uk). By Industry we mean researchers in the pharmaceutical, consumer goods, nutrigenomics, cosmaceutical and agriculture industries which all have an interest in health, disease and phenotypes.Registration Closed.
![]() |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||